# Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment

Source: https://onco.cc/trials/nct04807257/  
OnCo record `nct04807257` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Auger Molecular Therapy (AMT) in advanced solid tumours, run by NanoRay Biotech Co., Ltd., now recruiting.

## Summary

Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment is a phase 1/2 interventional study registered as NCT04807257 by NanoRay Biotech Co., Ltd., with 18 participants planned, started 2024-08-05 and due to reach its primary completion in 2025-12-31. Interventions recorded: Auger Molecular Therapy (AMT).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04807257
- Phase: 1/2
- Setting: A First-in-Human Study of Auger Molecular Therapy (AMT) in Patients With Malignant Cutaneous Lesions From Advanced Solid Tumors
- Sponsor: NanoRay Biotech Co., Ltd.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT04807257: https://clinicaltrials.gov/study/NCT04807257

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct04807257.json